Statement: More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 80/260 (30.77%)   Anaemia * 2/260 (0.77%)   Febrile neutropenia * 0/260 (0.00%)   Neutropenia * 2/260 (0.77%)   Thrombocytopenia * 0/260 (0.00%)   Bundle branch block right * 0/260 (0.00%)   Pericardial effusion * 0/260 (0.00%)   Cardiopulmonary failure * 0/260 (0.00%)   Aplasia * 0/260 (0.00%)   Eye symptom * 1/260 (0.38%)   Abdominal discomfort * 0/260 (0.00%) Adverse Events 2:   Total: 71/267 (26.59%)   Anaemia * 2/267 (0.75%)   Febrile neutropenia * 1/267 (0.37%)   Neutropenia * 0/267 (0.00%)   Thrombocytopenia * 1/267 (0.37%)   Bundle branch block right * 1/267 (0.37%)   Pericardial effusion * 5/267 (1.87%)   Cardiopulmonary failure * 1/267 (0.37%)   Aplasia * 1/267 (0.37%)   Eye symptom * 0/267 (0.00%)   Abdominal discomfort * 1/267 (0.37%)
Secondary_evidence: Adverse Events 1:   Total: 13/74 (17.57%)   neutropenia 1/74 (1.35%)   left ventricular dysfunction 1/74 (1.35%)   fistula enterovesical 1/74 (1.35%)   constipation and hypokalemia 1/74 (1.35%)   nausea, vomiting and burning abdominal pain 2/74 (2.70%)   Infection 1/74 (1.35%)   febrile neutropenia 3/74 (4.05%)   speech impairment 1/74 (1.35%)   dyspnea, pain 1/74 (1.35%)   hemorrhage/bleeding 2/74 (2.70%)